ARTICLE | Discovery & Translation
Each one may require different treatments and have different safety considerations
By Selina Koch, Executive Editor
January 18, 2024 8:02 PM UTC
Companies developing therapies for Alzheimer’s disease often point to the use of amyloid and tau-based biomarkers as the dawning of precision medicine in the field, but those biomarkers barely scratch the surface of what will eventually be needed to personalize treatment.
After what has felt like painfully slow progress in understanding why some patients progress faster than others, respond better to treatment or have greater safety risks, a Dutch research team stepped on the accelerator in a Nature Aging paper published last week. …